Market Place
Sourcing Support
Result of General Meeting
22 Nov 2024 //
GLOBENEWSWIRE
Biodexa Advances Two Recent Acquisitions Through the Clinic
21 Nov 2024 //
ACCESSWIRE
Biodexa Pharma Regains Compliance For Continued Listing on Nasdaq
12 Nov 2024 //
GLOBENEWSWIRE
Notice of General Meeting
07 Nov 2024 //
GLOBENEWSWIRE
Biodexa`s MX-110 Shows Promise in Recurrent Glioblastoma Treatment
17 Oct 2024 //
ACCESSWIRE
Biodexa Announces Successful Appeal of Nasdaq Delisting
15 Oct 2024 //
GLOBENEWSWIRE
Biodexa Updates On MTX110 Phase 1 Study In Glioblastoma
04 Oct 2024 //
GLOBENEWSWIRE
Interim results for the six months ended June 30, 2024
26 Sep 2024 //
GLOBENEWSWIRE
ADR Ratio Change
19 Sep 2024 //
GLOBENEWSWIRE
Announces Payment Of $3.0MM Final Match Payment For Grant
16 Sep 2024 //
GLOBENEWSWIRE
Receipt of Nasdaq Delisting Determination - Plans to Appeal
30 Aug 2024 //
GLOBENEWSWIRE
Company Closes $5.0 Million Offering And Private Placement
23 Jul 2024 //
GLOBENEWSWIRE
Biodexa Prices $5.0M Registered Direct Offering And Private Placement
19 Jul 2024 //
GLOBENEWSWIRE
Biodexa`s Phase 2a Study Of Tolimidone For T1D Approved In Canada
16 Jul 2024 //
GLOBENEWSWIRE
Biodexa Reports Positive 12-Month Data For eRapa In Precancerous Polyps
11 Jul 2024 //
ACCESSWIRE
MTX110 Phase 1 Data Shows Increased Survival In DMG Brain Cancer
02 Jul 2024 //
GLOBENEWSWIRE
Biodexa Announces Phase 2 Results of eRapa™ in Familial Adenomatous Polyposis
24 Jun 2024 //
GLOBENEWSWIRE
Results of Annual General Meeting
13 Jun 2024 //
GLOBENEWSWIRE
eRapa FAP Phase 2 Data To Be Presented At InSIGHT 2024 In Barcelona
10 Jun 2024 //
GLOBENEWSWIRE
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
22 May 2024 //
GLOBENEWSWIRE
Biodexa`s eRapa Shows Positive Phase 2 FAP Data At DDW 2024
21 May 2024 //
GLOBENEWSWIRE
Posting of Annual Report & Notice of AGM - Total Voting Rights
15 May 2024 //
GLOBENEWSWIRE
Biodexa Licenses Phase 3 Asset eRapa„ for FAP Treatment
26 Apr 2024 //
GLOBENEWSWIRE
Preliminary Results for the Year Ended 31 December 2023
19 Apr 2024 //
GLOBENEWSWIRE
Biodexa Announces Positive Ph I Trial Results for Diffuse Midline Glioma
23 Feb 2024 //
GLOBENEWSWIRE
Biodexa Reports Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma
08 Feb 2024 //
GLOBENEWSWIRE
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
07 Feb 2024 //
GLOBENEWSWIRE
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023
22 Jan 2024 //
GLOBENEWSWIRE
Biodexa Appoints Ann Merchant to the Board of Directors
29 Dec 2023 //
GLOBENEWSWIRE
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering
21 Dec 2023 //
GLOBENEWSWIRE
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
19 Dec 2023 //
GLOBENEWSWIRE
Biodexa Enters Into Agreements to Acquire Worldwide License to Tolimidone
27 Nov 2023 //
GLOBENEWSWIRE
Biodexa Completes Recruitment of Cohort A in Study of MTX110
03 Oct 2023 //
GLOBENEWSWIRE
Interim results for the six months ended 30 June 2023
29 Sep 2023 //
GLOBENEWSWIRE
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110
21 Sep 2023 //
GLOBENEWSWIRE
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
28 Jul 2023 //
GLOBENEWSWIRE
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
24 Jul 2023 //
GLOBENEWSWIRE
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110
10 Jul 2023 //
GLOBENEWSWIRE
